Shanghai OPM Biosciences Co. Ltd. A (688293.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005PF1

Price
57.01 CNY
Market cap
8.11 bn CNY
P/E (2025)
155.61
P/S (2025)
22.84
Dividend yield
0.70 %
Net margin
11.75 %
Return on equity (ROE)
1.99 %
Return on assets (ROA)
1.86 %

Shanghai OPM Biosciences Co. Ltd. A financials

Fiscal year20242025
Revenue297.24 m CNY354.91 m CNY
Gross profit157.62 m CNY180.47 m CNY
Operating income17.96 m CNY37.81 m CNY
EBIT39.54 m CNY52.07 m CNY
Net income21.05 m CNY41.70 m CNY
Diluted EPS – continuing operations0.18 CNY0.37 CNY

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Shanghai OPM Biosciences Co. Ltd. A

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, OPM-Vac platform, OPM-Hybri Platform, VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and product characterization of biologics. The company was founded in 2013 and is headquartered in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 03.11.2026. Details in the risk notice.